Mar 26 |
Stoke Therapeutics Announces Proposed Public Offering
|
Mar 26 |
Stoke Therapeutics' Anti-Epilepsy Drug Candidate Shows Substantial, Sustained Reductions In Seizure Frequency In Pretreated Patients
|
Mar 26 |
Stoke stock rockets 73% on updated epilepsy drug data
|
Mar 26 |
TD Cowen ups Stoke to buy on updated data for epilepsy drug
|
Mar 26 |
Stoke shares surge on updated results for Dravet drug
|
Mar 25 |
Stoke Therapeutics GAAP EPS of -$0.60 beats by $0.02, revenue of $2.8M misses by $0.42M
|
Mar 25 |
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Lags Revenue Estimates
|
Mar 25 |
Stoke stock soars 70% post-market on epilepsy drug data
|
Mar 25 |
Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome
|
Mar 25 |
Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
|